AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02070783
Drug: ARA290
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02070783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04068792
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in each Age Group (1,2,3) will receive matching placebo (volume placebo to match the calculated volume of the JNJ-53718678 dose) orally twice daily for 7 days.
Trial: NCT04068792
Drug: JNJ-53718678 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-53718678 will be administered to Age Group 2 twice daily for 7 days.
Trial: NCT04068792
Drug: JNJ-53718678 4.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-53718678 will be administered to Age Group 3 twice daily for 7 days.
Trial: NCT00725322
Drug: Placebo - Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Saline injection given at site of scar neuroma
Trial: NCT01318369
Drug: Namisol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose delta-9-tetrahydrocannabinol
Trial: NCT03517319
Drug: Normal Saline 0.9% 1.2 ml
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00730691
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching capsules
Trial: NCT00396175
Drug: Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02161679
Drug: IMMU-132 infusion is administered to participants in one arm for the study
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02043522
Drug: Radioisotope
RxNorm normalized name: Radioisotope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of 10 mCi (370 mBq:± 10%, calibrated to time of injection) of 123I-mIBG (AdreView) administered as a single intravenous bolus over 1 or 2 minutes, followed by a saline flush.
Trial: NCT01570361
Drug: Drug Treatment
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy (either rate or rhythm control): Class I or class III, or AV nodal blocking agents such as beta blockers and calcium channel blockers in accordance with current atrial fibrillation management guidelines.
Trial: NCT04129554
Drug: Placebo for JNJ-56136379
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for JNJ-56136379 tablets will be administered orally up to 48 weeks.
Trial: NCT01239004
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 tablets daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
Trial: NCT02101853
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02101853
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02101853
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT, IV, and PO
Trial: NCT02101853
Drug: Therapeutic Hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IT
Trial: NCT00379860
Drug: LXR-623
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02275468
Drug: Fu-zheng-qu-zhuo (FZQZ) oral liquid
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FZQZ oral liquid is a herbal medicine, composed of astragalus, angelica root, rhubarb, etc, with the effect of reinforcing Qi and activating blood, dissolving dampness and downbearing turbid.
Trial: NCT01871961
Drug: Methotrexate (Metoject® prefilled pen)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00874120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken twice daily (12 hours apart) for 7 days.
Trial: NCT02153645
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00477165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical to citalopram 20mg capsules; 1 capsule/day for 4 weeks, then 2 capsules/day for 4 weeks
Trial: NCT02879305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
Trial: NCT02879305
Drug: Iron therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.
Trial: NCT00039130
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/sq m/day IV infusion over 5-15 min days 1-5, courses I, III, V, VII
Trial: NCT00039130
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/sq m/day IV infusion Days 4 \& 5 courses III,V, VII
Trial: NCT00039130
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25mg/sq m IV infusion over 15 min then 10 mg IV q 6 hrs until serum MTX \<10nM, courses II-VII
Trial: NCT00039130
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.5 g/sq m IV infusion Day 1 courses II-VII
Trial: NCT00908713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium chloride 0.9% 10 mL every 12 h for 5 days
Trial: NCT01435200
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron 200 mg add in 0.9% Normal saline 100 ml infused within 15 minutes after every cycles of chemotherapy
Trial: NCT03471130
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, 7 days
Trial: NCT02983344
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl
Trial: NCT02854631
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg (4 x 10 mg tablets) administered orally once daily
Trial: NCT02854631
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selonsertib placebo tablet administered orally once daily
Trial: NCT04662125
Drug: caffeine, paracetamol tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral fluid intake, recumbent positioning, combination of paracetamol and caffeine tablet three times per day for three days (2 tablets of Panadol-Extra tablet, film coated, GlaxoSmithKline Consumer Healthcare Holdings (US) LLC were given every 8hours) and stool softener and to maintain blinding a tablet of vitamins was given twice per day for three days.
Trial: NCT04662125
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients who received conservative treatment as control group together with oral tablet prednisolone 20 mg once daily plus one tablet of vitamins to maintain blinding for three days. .
Trial: NCT01421004
Drug: TKI258
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04774328
Drug: CA-008 (vocacapsaicin)
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of CA-008 (vocacapsaicin) versus placebo
Trial: NCT04774328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of CA-008 (vocacapsaicin) versus placebo
Trial: NCT02872194
Drug: BAY987516, Y55-170
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 uL in one eye
Trial: NCT02872194
Drug: BAY987516, X72-151
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 uL in one eye
Trial: NCT02872194
Drug: BAY987516, Y49-034
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 uL in one eye
Trial: NCT02872194
Drug: Standard shampoo mixture (control)
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 uL in one eye
Trial: NCT02129400
Drug: Aer medicinalis Linde 100%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02790203
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NSAIDS
Trial: NCT02790203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01939652
Drug: Drag: Crystalloids and Colloids
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01375556
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02091492
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo teriparatide sc (subcutaneous injection) each day for 12 weeks
Trial: NCT02176499
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01206660
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered to affected area twice a day for 28 days
Trial: NCT02708160
Drug: 1.1% Fluoride toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
Trial: NCT02708160
Drug: 0.243% Fluoride toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
Trial: NCT00297375
Drug: tramadol HCl/acetaminophen
RxNorm normalized name: tramadol HCl/acetaminophen 37.5 mg-325 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03100019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04055012
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tabs
Trial: NCT00630396
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose level 1 = 3mg/kg intravenous (IV) initial dose, followed by 1.5mg/kg every 12 hours times 5 more doses.~Dose level 2 = 4.5mg/kg intravenous (IV) initial dose, followed by 2.25mg/kg every 12 hours times 5 more doses.~Dose level 3 = 6 mg/kg intravenous (IV) initial dose, followed by 3 mg/kg every 12 hours times 5 more doses.~Dose level 4 = 10 mg/kg intravenous (IV) initial dose, followed by 5 mg/kg every 12 hours times 5 more doses
Trial: NCT01991210
Drug: DNIB0600A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNIB0600A will be administered at a dose of 2.4 mg/kg IV every 3 weeks.
Trial: NCT01991210
Drug: PLD
RxNorm normalized name: PLD1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD will be administered at a dose of 40 mg/m\^2 IV every 4 weeks.
Trial: NCT04497688
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received a single dose of PEG-rhG-CSF per cycle. The chemotherapy regimen must meet the interval between two chemotherapy sessions at least 12 days.
Trial: NCT01432080
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months
Trial: NCT02198274
Drug: BIBH 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/week
Trial: NCT01277094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily doses for 12 weeks
Trial: NCT01277094
Drug: RO5093151
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily doses for 12 weeks
Trial: NCT03754244
Drug: TQB3456
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observe the safety and pk when the subjects take TQB3456 p.o. qd
Trial: NCT00571935
Drug: soluble human insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02092935
Drug: SMT19969
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00190593
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02323698
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will ingest capsules containing caffeine (up to 6mg/kg). Experiments will begin 30min after consumption to approximately coincide with peak plasma concentrations.Throughout the 30min wait time and experimentation, blood pressure and heart rate will be monitored.
Trial: NCT04325581
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline SC daily
Trial: NCT00507117
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT00989053
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill per day for 8 weeks
Trial: NCT03185208
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See placebo arm
Trial: NCT03669250
Drug: CVN058
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVN058 will be given at two doses, a low does and a high dose
Trial: NCT00297830
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug is administered through 5 mg intravenous infusion over 20 minutes
Trial: NCT02047890
Drug: BAY1000394 (2.5mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY1000934 2.5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 1)
Trial: NCT03341013
Drug: MEDI0382 Formulation 2
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequence 1 Period 1 and Sequence 2 Period 2.
Trial: NCT02047890
Drug: BAY1000394 (5mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY1000934 5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 2)
Trial: NCT03487276
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01823523
Drug: Cefazolin, Cephalexin, Clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00808366
Drug: Keratolytic/Antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intial treatment with RV4104A ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
Trial: NCT00808366
Drug: Keratolytic/Antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment with bifonazole-urea ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
Trial: NCT03018821
Drug: Standard - Ge Xia Zhu Yu Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ge Xia Zhu Yu Decoction is one Chinese Medicine Formula for the TCM syndrome: internal blood stasis.
Trial: NCT03018821
Drug: Advanced - Supplemented Taohong Huazhuo Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemented Taohong Huazhuo Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Damp-heat blocking middle jiao.
Trial: NCT03018821
Drug: Standard - Chaihu Shugan San
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chaihu Shugan San is one Chinese Medicine Formula for the TCM syndrome: Liver depression and qi stagnation.
Trial: NCT03018821
Drug: Advanced - Soothe the liver and regulate qi Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soothe the liver and regulate qi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Liver depression and qi stagnation.
Trial: NCT03018821
Drug: Standard - Xiaoyao powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiaoyao powder is one Chinese Medicine Formula for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
Trial: NCT03018821
Drug: Advanced - Supplemented Ganbi Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemented Ganbi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
Trial: NCT03018821
Drug: Standard - Yiguan Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiguan Decoction is one Chinese Medicine Formula for the TCM syndrome: Yin deficiency of liver and kidney.
Trial: NCT03018821
Drug: Advanced - Supplemented Zimu Dan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemented Zimu Dan is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yin deficiency of liver and kidney.
Trial: NCT03018821
Drug: Standard - Fuzilizhong Decoction plus Jinkui Shenqi Bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzilizhong Decoction plus Jinkui Shenqi Bolus is one Chinese Medicine Formula for the TCM syndrome: Yang deficiency of spleen and kidney.
Trial: NCT03018821
Drug: Advanced - Guifu Erxian Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guifu Erxian Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yang deficiency of spleen and kidney.
Trial: NCT03018821
Drug: Advanced - Supplemented Ganji Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemented Ganji Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: internal blood stasis.
Trial: NCT01847274
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02837328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
Trial: NCT01277991
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)
Trial: NCT01277991
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)
Trial: NCT00531323
Drug: TMC125 once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily
Trial: NCT00531323
Drug: TMC125 twice daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
Trial: NCT01695187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00723983
Drug: NP101 Study Patch
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NP101 study patch 4 hour application
Trial: NCT01867437
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile solution (vehicle) for subcutaneous infusion
Trial: NCT02781597
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 0.9% normal saline
Trial: NCT00003499
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Low-grade non-Hodgkin's lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT02864498
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01208194
Drug: MGN1703
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution, 60 mg, twice a week, until progression
Trial: NCT01208194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution, 60 mg, twice a week, until progression
Trial: NCT00021255
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00021255
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01015287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once orally
Trial: NCT04467151
Drug: anti-SARS-CoV-2 plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of anti-SARS-CoV-2 convalescent plasma
Trial: NCT01601405
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On Days 0 and 14, each subject took a placebo capsule. Each capsule taken with water 150 mL.
Trial: NCT00720538
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules